{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:14:38Z","timestamp":1769512478829,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ard-2023-224071","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T17:25:22Z","timestamp":1687195522000},"page":"1123-1129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Approach to vaccination in systemic lupus erythematosus on biological treatment"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-0212","authenticated-orcid":false,"given":"Re\u015fit","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David Alan","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224071_bib1","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1097\/MD.0000000000000794","article-title":"Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2023-224071_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra S\u00e1nchez","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib4","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/0961203316636472","article-title":"Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment","volume":"25","author":"Rezende","year":"2016","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib5","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T","article-title":"Antigen-specific antibody responses in lupus patients following immunization","volume":"41","author":"Battafarano","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib6","first-page":"498","article-title":"Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients","volume":"34","author":"Wallin","year":"2009","journal-title":"Acta Reumatol Port"},{"key":"10.1136\/ard-2023-224071_bib7","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/art.30388","article-title":"Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features","volume":"63","author":"Crowe","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with Rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2015.01.002","article-title":"Reasons for failure to receive pneumococcal and influenza Vaccinations among immunosuppressed patients with systemic lupus erythematosus","volume":"44","author":"Lawson","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1177\/0961203314543918","article-title":"Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections","volume":"23","author":"Luijten","year":"2014","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib13","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.vaccine.2009.01.127","article-title":"Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits","volume":"27","author":"Jansen","year":"2009","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2017.05.012","article-title":"Pneumococcal infection in patients with systemic lupus erythematosus","volume":"85","author":"Schurder","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2023-224071_bib15","first-page":"204","article-title":"Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus","volume":"13","author":"Alyasin","year":"2016","journal-title":"Iran J Immunol"},{"key":"10.1136\/ard-2023-224071_bib16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices \u2014 United States","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ard-2023-224071_bib17","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2017.07.094","article-title":"Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study","volume":"35","author":"Grabar","year":"2017","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib18","first-page":"1118","article-title":"Pneumococcal immunization in patients with systemic lupus erythematosus treated with Immunosuppressives","volume":"12","author":"Lipnick","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u0391, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224071_bib20","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on Immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3899\/jrheum.150397","article-title":"Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases","volume":"43","author":"Broyde","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1136\/annrheumdis-2017-212789","article-title":"Impaired long-term immune protection following pneumococcal 13-valent\/23-Valent polysaccharide vaccine in systemic lupus erythematosus (SLE)","volume":"77","author":"Sacre","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.autrev.2018.08.002","article-title":"Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis","volume":"18","author":"Adawi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2023-224071_bib25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib26","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of Belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib27","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib29","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib30","doi-asserted-by":"crossref","first-page":"37817","DOI":"10.1038\/srep37817","article-title":"Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224071_bib31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/ard.47.7.532","article-title":"In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases","volume":"47","author":"Turner-Stokes","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","article-title":"Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis","volume":"55","author":"Pug\u00e8s","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224071_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/acr.20465","article-title":"Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases","volume":"63","author":"Elkayam","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224071_bib34","first-page":"2555","article-title":"Specific antibody response after influenza immunization in systemic lupus erythematosus","volume":"29","author":"Abu-Shakra","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib35","first-page":"16","article-title":"Influenza vaccination of patients with systemic lupus erythematosus","volume":"56","author":"Mercado","year":"2004","journal-title":"Rev Invest Clin"},{"key":"10.1136\/ard-2023-224071_bib36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2005.043943","article-title":"Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease","volume":"65","author":"Holvast","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10067-010-1373-y","article-title":"Anti-influenza vaccination in systemic lupus erythematosus patients: ananalysis of specific humoral response and vaccination safety","volume":"29","author":"Wiesik-Szewczyk","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib38","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib39","doi-asserted-by":"crossref","first-page":"e0147856","DOI":"10.1371\/journal.pone.0147856","article-title":"Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-224071_bib40","doi-asserted-by":"crossref","first-page":"e3637","DOI":"10.1097\/MD.0000000000003637","article-title":"Is systemic lupus erythematosus associated with a declined Immunogenicity and poor safety of influenza vaccination?: a systematic review and meta-analysis","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2023-224071_bib41","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kep200","article-title":"Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study","volume":"48","author":"Holvast","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224071_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with Rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224071_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of Rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of A\/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224071_bib45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12390","article-title":"Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients","volume":"178","author":"Westra","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard-2023-224071_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib48","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.41456","article-title":"COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes","volume":"72","author":"Haberman","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib49","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib50","doi-asserted-by":"crossref","first-page":"105095","DOI":"10.1016\/j.jbspin.2020.105095","article-title":"COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence","volume":"88","author":"Costantino","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2023-224071_bib51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers Immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib52","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib53","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-Cov-2 in patients with a history of CD20 B-cell-depleting therapy (rituxivac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.41914","article-title":"Humoral and cellular immune responses to SARS-Cov-2 infection and vaccination in autoimmune disease patients with B cell depletion","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib55","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","article-title":"Efficacy and safety of SARS-Cov-2 revaccination in non-responders with immune-mediated inflammatory disease","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib56","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard-2022-222550","article-title":"Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study","volume":"81","author":"Furer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib57","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S2665-9913(23)00004-8","article-title":"Breakthrough SARS-Cov-2 infections and prediction of moderate-to-severe outcomes during Rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study","volume":"5","author":"Md Yusof","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-Cov-2","volume":"601","author":"Swadling","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2023-224071_bib59","doi-asserted-by":"crossref","first-page":"e002036","DOI":"10.1136\/rmdopen-2021-002036","article-title":"Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-Cd20 therapies: a systematic review and meta-analysis of 1342 patients","volume":"8","author":"Schietzel","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224071_bib60","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/rheumatology\/keac459","article-title":"Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus","volume":"62","author":"Boedecker-Lips","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224071_bib61","doi-asserted-by":"crossref","first-page":"102827","DOI":"10.1016\/j.jaut.2022.102827","article-title":"High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients","volume":"129","author":"Fabris","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-224071_bib62","first-page":"e60","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib63","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-Cov-2","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224071_bib64","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/kez045","article-title":"Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study","volume":"58","author":"B\u00fchler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224071_bib65","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-224071_bib67","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes Zoster vaccination in SLE: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib68","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of Inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 Monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib69","author":"Agency EM"},{"key":"10.1136\/ard-2023-224071_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/RHU.0000000000000877","article-title":"Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and\/or Biologics therapy","volume":"25","author":"Intongkam","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2023-224071_bib71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0961203318819827","article-title":"Hepatitis A virus vaccination in childhood-onset systemic lupus erythematosus","volume":"28","author":"Mertoglu","year":"2019","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224071_bib72","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2019.11.034","article-title":"Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies","volume":"38","author":"Einarsdottir","year":"2020","journal-title":"Vaccine"},{"key":"10.1136\/ard-2023-224071_bib73","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442308X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442308X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:37:52Z","timestamp":1749807472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672442308X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S000349672442308X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224071","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to vaccination in systemic lupus erythematosus on biological treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}